We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Gestational Diabetes May Predict Autoimmune Diabetes Risk

By LabMedica International staff writers
Posted on 15 Jun 2021
Print article
Image: Women diagnosed with gestational diabetes are more likely to be autoantibody positive and develop type 1 diabetes in the decade after delivery compared with pregnant women without gestational diabetes (Photo courtesy of Kernodle Clinic)
Image: Women diagnosed with gestational diabetes are more likely to be autoantibody positive and develop type 1 diabetes in the decade after delivery compared with pregnant women without gestational diabetes (Photo courtesy of Kernodle Clinic)
Gestational diabetes is high blood sugar (glucose) that develops during pregnancy and usually disappears after giving birth. It can happen at any stage of pregnancy, but is more common in the second or third trimester.

Autoimmune diabetes, commonly referred to as type 1 diabetes mellitus (an older synonym is insulin-dependent diabetes mellitus), is a chronic immune-mediated disease characterized by insulin deficiency due to pancreatic islet beta-cell destruction with increasing blood glucose levels.

Medical Scientists at the Helsinki University Hospital (Helsinki, Finland) in a prospective cohort study, analyzed data from 391 women with gestational diabetes and 391 age-, parity- and delivery date-matched controls who delivered from 1984 through 1994 and underwent autoantibody testing during the first trimester of pregnancy. The team assessed levels of four autoantibodies associated with type 1 diabetes: Islet cell autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA), insulin autoantibodies (IAA) and insulinoma-associated antigen-2 autoantibodies (IA-2A). Women completed a follow-up questionnaire assessing later type 1 or type 2 diabetes diagnosis in 2012-2013. The mean follow-up time was 23 years.

The scientists observed single autoantibody positivity in 41(12%) of the gestational diabetes cohort and in eight (2.3%) of the control cohort. In the gestational diabetes cohort, nine (2.6%) tested positive for two autoantibodies and eight (2.3%) tested positive for three autoantibodies, whereas only one woman in the control cohort had two autoantibodies detected. Islet cell autoantibodies (ICA) positivity was found in 12.5% of cases, followed by GADA (6%), IA-2A (4.9%) and IAA (1.2%). In the control cohort, GADA positivity was found in 1.4% of cases, followed by IA-2A (0.8%), IAA (0.6%) and ICA (0.3%). All women with three positive autoantibodies developed type 1 diabetes within seven years from pregnancy with gestational diabetes. Development of type 2 diabetes and gestational diabetes occurred independent of autoantibody positivity.

Kaisu Luiro-Helve, MD, PhD, consultant in obstetrics and gynecology and reproductive endocrinology and senior author of the study, said, “If you are not the typical gestational diabetes candidate, but you have it, that may warrant more screening. Type 1 diabetes is not just a disease of the young. Type 1 usually occurs within 10 years of gestational diabetes, and that is the time when we need to stay alert and perhaps conduct another oral glucose tolerance test. Do not forget about these women after delivery.” The study was presented at the European Congress of Endocrinology virtual meeting held May 22-26, 2021.

Related Links:
Helsinki University Hospital

New
Platinum Supplier
Hormonal Test
Endocrine Array
New
POC BNP Fluorescence Immunoassay
Quidel Triage BNP Test
New
Multiplex Molecular Panel
ARIES Flu A/B & RSV+SARS‑CoV‑2 Assay (CE-IVD)
New
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg

Print article

Channels

Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.